Tempus AI reported total contract value of $1.1 billion through the first three quarters of 2025, driven by accelerating adoption of its AI-enabled precision medicine platform. The company posted its first positive adjusted EBITDA in Q3 2025, reversing cumulative quarterly losses of 2024. Subscription revenues from its clinical testing and data-analytics services grew 45% year-over-year, contributing the bulk of operating margin improvements as Tempus continues to scale its infrastructure and expand its mixed-revenue model.

During the same period, Tempus secured more than 70 data-sharing agreements with leading pharmaceutical and biotech firms to support drug discovery and clinical trial design. These partnerships leverage Tempus’s multimodal data library—now encompassing over 200,000 de-identified patient records—and grant partners access to longitudinal genomic, imaging and clinical data. The deals are expected to generate incremental analytics revenue over multi-year terms and accelerate Tempus’s strategic push into companion diagnostic development.

In November 2025, Tempus introduced Paige Predict, an AI-powered digital pathology application that analyzes a single hematoxylin and eosin slide to predict the presence or absence of 123 actionable biomarkers across 16 cancer types. Built on a foundation model trained with data from Tempus and Paige, the solution delivers predictions directly within the clinical report, reducing ‘quantity not sufficient’ sample rates by up to 30%. Early validation studies report concordance rates above 90% versus standard molecular assays, positioning Paige Predict as a front-line tool for optimizing next-generation sequencing workflows.